(Q41645946)

English

Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction

scientific article published on October 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

pharmacotherapy

0 references

coronary artery disease

1 reference

based on heuristic

inferred from title

ventricular dysfunction

1 reference

based on heuristic

inferred from title

author name string

R J Simpson

1

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

C A Sueta

2

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

S J Boccuzzi

3

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

A Lulla

4

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

D Biggs

5

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

A Londhe

6

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

S C Smith

7

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

language of work or name

0 references

publication date

1 October 1997

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

80

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

8B

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

53H-56H

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. The Clinical Quality Improvement Network (CQIN) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Inadequate management of hyperlipidaemia after coronary bypass surgery shown by medical audit

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Cholesterol awareness and treatment in patients with coronary artery disease participating in cardiac rehabilitation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900821-7

7 January 2021

Identifiers

10.1016/S0002-9149(97)00821-7

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41645946&oldid=2067304268"